Compare OMDA & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OMDA | CTNM |
|---|---|---|
| Founded | 2011 | 2009 |
| Country | United States | United States |
| Employees | 868 | N/A |
| Industry | Medical/Nursing Services | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 711.1M | 480.5M |
| IPO Year | N/A | 2024 |
| Metric | OMDA | CTNM |
|---|---|---|
| Price | $13.12 | $13.24 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 4 |
| Target Price | ★ $21.73 | $19.00 |
| AVG Volume (30 Days) | ★ 846.7K | 281.8K |
| Earning Date | 05-17-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 0.46 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $24.94 | N/A |
| Revenue Next Year | $20.18 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.28 | $3.35 |
| 52 Week High | $26.92 | $16.33 |
| Indicator | OMDA | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 53.72 | 48.70 |
| Support Level | $10.28 | $10.17 |
| Resistance Level | $16.93 | $13.18 |
| Average True Range (ATR) | 0.77 | 0.80 |
| MACD | 0.02 | 0.04 |
| Stochastic Oscillator | 87.23 | 45.27 |
Omada Health Inc empowers individuals to make lasting health changes through personalized, virtual care between doctor's visits. The integrated platform of the company supports members with cardiometabolic conditions like prediabetes, diabetes, hypertension, musculoskeletal issues, and behavioral health needs. The company's specialized care tracks also assist members using GLP-1 medications. The Company delivers measurable health outcomes and value for employers, health plans, health systems, and pharmacy benefit managers.
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.